|Bid||5.62 x 1100|
|Ask||5.78 x 900|
|Day's Range||5.62 - 5.88|
|52 Week Range||5.07 - 15.45|
|Beta (3Y Monthly)||2.52|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Champions Oncology, Inc. (NASDAQ:CSBR), which is in the life sciences business, and is based in United States, saw...
Ronnie Morris has been the CEO of Champions Oncology, Inc. (NASDAQ:CSBR) since 2017. This report will, first, examine...
Champions Oncology Inc (CSBR) files its latest 10-K with SEC for the fiscal year ended on April 30, 2019. Continue reading...
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...
Today we will run through one way of estimating the intrinsic value of Champions Oncology, Inc. (NASDAQ:CSBR) by...
It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Every investor in Champions Oncology, Inc. (NASDAQ:CSBR) should be aware of the most powerful shareho...
Champions Oncology, Inc. (CSBR) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.
During Champions Oncology's (CSBR) third-quarter fiscal 2019 conference call, investor focus will be on the company's progress with its Ex Vivo platform and services.
Champions Oncology (CSBR) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.